Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 22, 2024
Management Tracks
Blank slate at BioMarin for Sabry as dealmaker gets back to biotech
Company also adds Friberg to lead R&D, continuing the rebuild of its leadership team with former Genentech, Roche, Amgen execs
BioCentury | Oct 20, 2023
Deals
Oct. 20 Quick Takes: GSK adds ADC through Hansoh deal
Plus: Abivax raises $236M in NASDAQ debut, stock falls and updates from Arcutis, Pfizer, BioMarin, Angitia, InflamaX, Euregen and Rezubio
BioCentury | Jun 22, 2022
Deals
June 21 Quick Takes: Precision, Novartis in gene editing collaboration
Plus Galapagos acquires two companies, BioMarin gains an approval in Japan and updates from Merck & Co., BeiGene, Therorna, Acer and more
BioCentury | Feb 11, 2022
Deals
Feb. 10 Quick Takes: RA, Adjuvant ready Curevo to take on Shingrix with $60M A round
Seagen slides on guidance, and updates from Arkuda, Altesa, Aeglea, Congruence, 1859 and more
BioCentury | Dec 23, 2021
Product Development
First-in-class drugs fill FDA’s 2021 class of new approvals
Products against new targets accounted for nearly one third of NMEs, and fewer of them were for cancer than you might think
BioCentury | Nov 20, 2021
Regulation
Accelerated approval of BioMarin’s dwarfism drug clarifies endpoint
Growth velocity becomes an intermediate clinical endpoint, with final adult height data to come
BioCentury | Aug 28, 2021
Product Development
Aug. 27 Quick Takes: BioMarin gains first worldwide approval for achondroplasia therapy
Plus: Roche’s Tecentriq withdrawal, a16z’s seed fund, Lynk’s venture round and more
BioCentury | Jun 26, 2021
Regulation
CHMP’s recommendations for June
Along with a positive opinion for Opdivo nivolumab to treat adult patients with esophageal or gastroesophageal junction cancer, Bristol Myers Squibb Co. (NYSE:BMY) also received a recommendation
BioCentury | Nov 3, 2020
Regulation
BioMarin’s vosoritide clears regulatory hurdle as FDA sets goal date
Although BioMarin’s NDA for its achondroplasia treatment doesn’t quite match up with an FDA advisory committee’s recommendation for review, the agency has accepted the
BioCentury | Aug 15, 2020
Product Development
Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol
CanSino vaccine stops COVID-19 in mice, ferretsMice given a single intranasal immunization with Ad5-nCoV from CanSino Biologics Inc. (HKEX:6185; Shanghai:688185) and then challenged with mouse-adapted
Items per page:
1 - 10 of 37